Item 5.07 Submission of Matters to Vote of Security Holders

Monte Rosa Therapeutics, Inc (the "Company") held its Annual Meeting of Stockholders on June 15, 2022 (the "Annual Meeting") in a virtual-only format via live webcast. At the Annual Meeting, the Company's stockholders of record as of April 20, 2022 (the "Record Date") considered and voted on the two proposals set forth below, each of which is described in greater detail in the Company's Proxy Statement, filed with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended on April 27, 2022. As of the Record Date, the number of shares of the Company's common stock, $0.0001 par value per share ("Common Stock"), outstanding and entitled to vote at the Annual Meeting was 46,656,249. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 43,785,969, thus establishing a quorum for the Annual Meeting. Shares present virtually during the Annual Meeting were considered shares of Common Stock represented in person at the Annual Meeting. Each share of Common Stock was entitled to one vote with respect to matters submitted to the Company's stockholders at the Annual Meeting. The final voting results are set forth below.

The following is a summary of the matters voted on at the Annual Meeting.

Proposal 1 - Election of Class I Director Nominees

The stockholders of the Company elected Christine Siu, M.B.A. and Kimberly L. Blackwell, M.D. as Class I directors of the Company, each for a three-year term ending at the annual meeting of stockholders to be held in 2025 and until their successor have been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders' vote with respect to the election of the Class I directors were as follows:



                                Votes        Votes      Broker
                                 For       Withheld    Non-Votes

Christine Siu, M.B.A. 40,031,134 1,535,338 2,219,497 Kimberly L. Blackwell, M.D. 34,701,825 6,853,459 2,230,685

Proposal 2 - Ratification of Appointment of the Company's Independent Registered Public Accounting Firm

The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. The results of the stockholders' vote with respect to such ratification were as follows:




  Votes       Votes
   For       Against   Abstain
43,776,605    1,664     7,700

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses